BioSpace News Archive

BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company’s stock has been included in the Hang Seng Composite Index, effective September 6, 2021.

HUTCHMED Limited announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Hang Seng Indexes Company Limited, including the Hang Seng Composite Index, in accordance with the latest index series release by Hang Seng, with effect from Monday, September 6, 2021.